Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Abstract

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461.).

Keywords

Affiliated Institutions

• Biology of Infection FR
• Emory University US
• National Institute of Allergy and Infectious Diseases US
• Moderna Therapeutics (United States) US
• University of Maryland, Baltimore US
• Kaiser Permanente Washington Health Research Institute US
• Children's Healthcare of Atlanta US
• HOPE Clinic US
• Bipar FR
• University of North Carolina at Chapel Hill US
• Emmes (United States) US
• National Institutes of Health US

Related Publications